Grant: Fellowship - PA: Biomedical / Clinical HIV/AIDS Research
Direct Payment
$141,667.00
Impact of HIV specific antibodies on the initial events of HIV infection in the human vaginal mucosa
FY 2010-11
Summary
The HIV pandemic continues to be a major threat to public health worldwide. Sexual transmission accounts for the majority of new cases and women are most frequently infected. While current prophylactic strategies provide some benefit, the best hope for ending the pandemic is the development of a protective vaccine. Such a vaccine must be effective at blocking viral entry, which, in the case of sexual transmission in women, occurs at mucosal surfaces of the genital tract. Thus, an understanding of the immune mechanisms that can inhibit the earliest steps of HIV entry into target cells at these surfaces is critical. An effective antibody response is thought to be important for protection, as several studies using non-human primate models of HIV infection suggest that the presence of certain types of HIV-specific antibodies (neutralizing antibodies) can provide protection against vaginal exposure to HIV. Neutralizing antibodies lower HIV infectivity by binding to the viral surface thereby preventing attachment or entry into target cells. Antibodies may potentially perform several functions, in addition to neutralization, that contribute to preventing HIV infection at the mucosa. However, these functions remain largely unexplored in a mucosal setting. We propose to use a novel vaginal infection model to shed light on these mechanisms. In this model, discarded tissue from routine vaginal repair surgeries is collected and processed into tiny sheets of epithelia (the top layer of the mucosa), which are then exposed to HIV in the presence of various antibodies. The epithelia contain the first target cells HIV encounters during vaginal exposure, allowing us to investigate the function of HIV-specific antibodies during the initial events that establish infection in the genital mucosa. We expect that these studies will help uncover key properties of protective antibodies and ultimately guide the development of improved vaccine candidates.
Department
Program
Fellowship - PA: Biomedical / Clinical HIV/AIDS Research
Recipient
Location
Washington, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
230272
Name
Astronomo Rena D
Region
Washington
Country
United States of America
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Impact of HIV specific antibodies on the initial events of HIV infection in the human vaginal mucosa
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$141,667
Cihrequipment2
$0
Programname2
Fellowship - PA: Biomedical / Clinical HIV/AIDS Research
Keyworddelim
Antibodies; Confocal Microscopy; Ex Vivo Infection Assay; Hiv Infection; Langerhans And Cd4 T Cells; Mucosal Immunology; Qpcr; Vaccine; Vaginal Explant; Viral Transmission/Inhibition
Abstract
The HIV pandemic continues to be a major threat to public health worldwide. Sexual transmission accounts for the majority of new cases and women are most frequently infected. While current prophylactic strategies provide some benefit, the best hope for ending the pandemic is the development of a protective vaccine. Such a vaccine must be effective at blocking viral entry, which, in the case of sexual transmission in women, occurs at mucosal surfaces of the genital tract. Thus, an understanding of the immune mechanisms that can inhibit the earliest steps of HIV entry into target cells at these surfaces is critical. An effective antibody response is thought to be important for protection, as several studies using non-human primate models of HIV infection suggest that the presence of certain types of HIV-specific antibodies (neutralizing antibodies) can provide protection against vaginal exposure to HIV. Neutralizing antibodies lower HIV infectivity by binding to the viral surface thereby preventing attachment or entry into target cells. Antibodies may potentially perform several functions, in addition to neutralization, that contribute to preventing HIV infection at the mucosa. However, these functions remain largely unexplored in a mucosal setting. We propose to use a novel vaginal infection model to shed light on these mechanisms. In this model, discarded tissue from routine vaginal repair surgeries is collected and processed into tiny sheets of epithelia (the top layer of the mucosa), which are then exposed to HIV in the presence of various antibodies. The epithelia contain the first target cells HIV encounters during vaginal exposure, allowing us to investigate the function of HIV-specific antibodies during the initial events that establish infection in the genital mucosa. We expect that these studies will help uncover key properties of protective antibodies and ultimately guide the development of improved vaccine candidates.
Competitiondate
201102
Approvedterm2
2 yrs 10 mths
Pinamesdelim
Astronomo, Rena D
Approvedterm
2 ans 10 mois
Cihrcontribution2
~ $141,667~ $0~